Wall Street Zen cuts CVS Health to Buy. CVS Health stock falls 1.09 percent

Published on 10/19/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The rating changed to Buy on October 19, 2026. CVS Health stock costs EUR 81.88, 1.09 percent below the October 16 Xetra close of EUR 82.78.

Rating change and earnings date

On October 19, 2026, Wall Street Zen changed CVS Health's rating from Strong Buy to Buy.
Second-quarter 2026 revenue reached USD 106.10 billion, up 7.30 percent year over year.
CVS Health stock trades at EUR 81.88 at 10:00 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.09 percent below the Xetra close of October 16, 2026.
CVS Health will discuss third-quarter 2026 results on November 4, 2026.

Bauhaus-Stil-Poster mit geometrischen Primärfarben und HEALTHCARE-Schriftzug im Modernismus-Design — CVS Health Corp. Bauhaus-Poster zeigt HEALTHCARE-Schriftzug mit kräftigen geometrischen Primärfarben, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health stock (ISIN US1266501006) was trading at EUR 81.88 at Lang & Schwarz on October 19, 2026 at 10:00 a.m. CEST, down 1.09 percent versus the Xetra close of October 16, 2026 at EUR 82.78. MarketBeat reported on October 19, 2026 that Wall Street Zen downgraded CVS Health from Strong Buy to Buy.

October 19 rating change

The downgrade is the latest dated analyst signal around CVS Health. The same MarketBeat report cited a broader consensus of 20 Buy ratings and three Holds, with an average target of USD 107.80. That target sits above the stock's reported US market quote, but the rating change adds a more cautious data point to the mix.

What did the quarter deliver?

CVS Health's second-quarter 2026 revenue rose 7.30 percent year over year to USD 106.10 billion, while earnings per share reached USD 2.58 against a USD 1.87 consensus estimate, according to MarketBeat. The revenue comparison provides the clearest operating measure in the latest reported period, while the earnings comparison shows the result exceeded expectations by USD 0.71 per share.

Three dated CVS events

On August 5, 2026, CVS Health reported second-quarter revenue of USD 106.10 billion and earnings per share of USD 2.58, as MarketBeat reported; on October 5, 2026, CVS Health scheduled its third-quarter results call for November 4, 2026, according to CVS Health; on October 19, 2026, Wall Street Zen changed the rating from Strong Buy to Buy, as reported by MarketBeat.

Upcoming November dates

CVS Health is scheduled to pay its quarterly dividend on November 2, 2026, with an ex-dividend date of October 22, 2026, according to MarketBeat. The company will discuss third-quarter 2026 financial results on November 4, 2026, at 8:00 a.m. ET, according to CVS Health.

Stock stays below its October close

CVS Health stock was trading at EUR 81.88 at Lang & Schwarz on October 19, 2026 at 10:00 a.m. CEST, 1.09 percent below the Xetra close of October 16, 2026 at EUR 82.78. The primary listing is on the NYSE, where the stock opened at USD 92.41 on October 19, 2026, according to MarketBeat. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.